v3.25.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 101,654 $ 153,290
Short-term restricted cash 1,330 160
Investment in equity securities 3,529 161
Trade and other receivables, net 1,839 1,004
Short-term royalty and commercial payment receivables under the EIR method 14,763 0
Short-term royalty and commercial payment receivables under the cost recovery method 413 14,215
Prepaid expenses and other current assets 2,076 483
Total current assets 125,604 169,313
Long-term restricted cash 3,432 6,100
Property and equipment, net 32 25
Operating lease right-of-use assets 319 378
Long-term royalty and commercial payment receivables under EIR method 4,970 0
Long-term royalty and commercial payment receivables under the cost recovery method 55,936 57,952
Exarafenib milestone asset (Note 4) 3,214  
Intangible assets, net 25,909  
Other assets - long term 1,861 533
Total assets 221,277 234,301
Current liabilities:    
Accounts payable 1,053 653
Accrued and other liabilities 5,752 2,768
Contingent consideration under RPAs, AAAs, and CPPAs 3,000 7,000
Operating lease liabilities 446 54
Unearned revenue recognized under units-of-revenue method 1,361 2,113
Preferred stock dividend accrual 1,368 1,368
Current portion of long-term debt 11,394 5,543
Total current liabilities 24,374 19,499
Unearned revenue recognized under units-of-revenue method - long-term 4,410 7,228
Exarafenib milestone contingent consideration (Note 4) 3,214  
Long-term operating lease liabilities 483 335
Long-term debt 106,875 118,518
Total liabilities 139,356 145,580
Commitments and Contingencies (Note 13)
Stockholders' equity:    
Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,952,377 and 11,495,492 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 90 86
Additional paid-in capital 1,318,766 1,311,809
Accumulated other comprehensive income 73  
Accumulated deficit (1,237,057) (1,223,223)
Total stockholders' equity 81,921 88,721
Total liabilities and stockholders' equity 221,277 234,301
8.625% Series A Cumulative, Perpetual Preferred Stock    
Stockholders' equity:    
Preferred Stock 49 49
8.375% Series B Cumulative, Perpetual Preferred Stock    
Stockholders' equity:    
Preferred Stock
Convertible preferred stock    
Stockholders' equity:    
Preferred Stock

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL